Guerbet (GBT) Q4 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 TU earnings summary
6 Jun, 2025Executive summary
Full-year 2024 revenue reached €841.1 million, up 7.1% year-over-year, or 9.0% at constant exchange rates and like-for-like basis, driven by strong growth in the Americas and Asia despite contraction in France.
Growth momentum continued for the second consecutive year, closely matching annual guidance.
Financial highlights
Restated EBITDA margin expected to be close to 14.9% for 2024.
Free cash flow anticipated to be slightly negative due to late payments in France.
Significant improvement in net debt/EBITDA ratio expected.
Unfavorable currency effect of €12.3 million, mainly from South American and Asian currencies.
Outlook and guidance
Profitability target for 2024 raised, with confidence in achieving a restated EBITDA margin near 14.9%.
Financial objectives for 2025 to be specified at the March 26, 2025, annual results release.
Latest events from Guerbet
- Net loss of €112.7 million driven by impairment, with 2026 outlook negatively impacted by Raleigh site.GBT
H2 202511 Mar 2026 - 2025 revenue fell 3.5% at CER, but EBITDA margin and cash flow outlooks remain positive.GBT
Q4 2025 TU5 Feb 2026 - Q3 2025 marked a return to growth, led by Elucirem™ and LipiodolⓇ momentum.GBT
Q3 2025 TU23 Oct 2025 - Revenue and profit declined in H1 2025, leading to lower guidance and cost focus.GBT
H1 202525 Sep 2025 - H1 revenue fell 5.4% at CER, but double-digit growth is expected in H2 as France recovers.GBT
Q2 2025 TU24 Jul 2025 - Strong H1 2024 growth and profitability led to raised guidance and improved financial metrics.GBT
H1 202413 Jun 2025 - Revenue up 8.1% to €620.5m, driven by Americas and Asia, with 2024 growth above 9% expected.GBT
Q3 2024 TU13 Jun 2025 - H1 2024 revenue up 11.8% at CER, with 2024 growth and margin guidance reaffirmed.GBT
Q2 2024 TU13 Jun 2025 - Q1 2025 revenue declined 7.3%, but annual growth and margin targets remain on track.GBT
Q1 2025 TU6 Jun 2025